Biotest Pharmaceuticals names new chief executive
Jordan Siegel is promoted from chief financial officer
BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.
Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.
BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.
You may also like
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing
ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity
The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Pharmaceutical
CelLBxHealth and AstraZeneca sign Master Services Agreement
The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform
Research & Development
Pfizer and Innovent Biologics strike $10.5bn oncology deal spanning 12 cancer programmes
The global licensing and co-development agreement covers a pipeline of ADCs and multi-specific antibodies, combining Innovent's discovery engine with Pfizer's clinical and commercial scale